Klotho and Bone Mineral Density (BMD) in Systemic Sclerosis Patients: Relationship with Microvascular Damage and Fibrosis
Status: Completed
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The present study recruits female patients aged 45-65 years with a diagnosis of Systemic Sclerosis according to the EULAR/ACR 2013 criteria and age and gender-matched healthy control subjects. The purpose of the study is to investigate the possible role of Klotho and other cytokines involved in the osteoimmunological control of bone turnover as a possible determinant of the microvascular damage and fibrosis observed in SSc patients
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Maximum Age: 65
Healthy Volunteers: t
View:
• Female gender
• Systemic sclerosis diagnosis
• Signature of the informed consent
Locations
Other Locations
Italy
Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS
Rome
Time Frame
Start Date: 2022-03-21
Completion Date: 2024-04-30
Participants
Target number of participants: 126
Treatments
Systemic Sclerosis patients
Female patients with systemic sclerosis with an age between 45 and 65 years old and did not met the exclusion criteria. Blood sample were collected to determine DKK1, Sclerostin Klotho and Osteoprotegerin. Bone mineral density was assessed. No drug was tested during the study.
Healthy subjects
Female patients with no history of inflammatory rheumatic disease and who di not met the exclusion criteria. Blood sample were collected to determine DKK1, Sclerostin Klotho and Osteoprotegerin. Bone mineral density was assessed. No drug was tested during the study.
Related Therapeutic Areas
Sponsors
Leads: Fondazione Policlinico Universitario Agostino Gemelli IRCCS